- Home
- DLXY vs APLT Comparison
DLXY vs APLT Comparison
Compare DLXY & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DLXY | APLT |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9M | 14.4M |
| IPO Year | 2025 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DLXY | APLT |
|---|---|---|
| Price | $0.91 | $0.10 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $1.25 |
| AVG Volume (30 Days) | 59.3K | ★ 10.6M |
| Earning Date | 03-13-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1077.13 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $273,155,000.00 | $1,000,000.00 |
| Revenue This Year | N/A | $124.18 |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | $14.37 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.61 | $0.09 |
| 52 Week High | $7.16 | $1.50 |
Technical Indicators
Market Signals| Indicator | DLXY | APLT |
|---|---|---|
| Relative Strength Index (RSI) | 49.55 | 35.60 |
| Support Level | $0.82 | $0.09 |
| Resistance Level | $1.12 | $0.11 |
| Average True Range (ATR) | 0.13 | 0.01 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 32.81 | 64.65 |
Price Performance
Historical ComparisonAbout DLXY Delixy Holdings Limited Ordinary Shares
Delixy Holdings Ltd a holding company that operates through subsidiary. It is engaged in the trading of oil-related products, which can be categorized into crude oil, and oil-based products such as naphtha, motor gasoline, gas oil, fuel oil, asphalt, base oil, and other petrochemicals. The company has two reportable segments: the Sale of crude oil and the Sale of oil-based products. Key revenue is generated from the Sale of crude oil.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.